UWM
LCTX icon

USAdvisors Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

USAdvisors Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,869
Closed -$12K – 130
2023
Q3 		$12K Hold
10,869
– – 0.01% 105
2023
Q2 		$15K Hold
10,869
– – 0.01% 103
2023
Q1 		$16K Hold
10,869
– – 0.01% 114
2022
Q4 		$13K Hold
10,869
– – 0.01% 109
2022
Q3 		$12K Buy
+10,869
New +$16K 0.01% 114
2022
Q2 		– Sell
-10,869
Closed -$17K – 114
2022
Q1 		$17K Buy
+10,869
New +$16.9K 0.01% 125

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return